OKYO vs ONCY

OKYO Pharma Limited vs Oncolytics Biotech Inc. — Valuation Comparison 2026

OKYO

Biotechnology
OKYO Pharma Limited
Quality
1.7
out of 10
Value Trap
Price
$1.71
Last close
Models
8/13
Active
VS

ONCY

Biotechnology
Oncolytics Biotech Inc.
Quality
3.4
out of 10
Value Trap
Price
$0.94
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType OKYO Fair ValueOKYO Upside ONCY Fair ValueONCY Upside
Bayesian DCF Intrinsic $0.45 -73.5% $0.27 -70.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.66 -61.1% $0.16 -82.7%
PWERM Option-Based $1.04 -38.7% $0.99 +6.2%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for OKYO vs ONCY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OKYO vs ONCY — Which Stock Is More Undervalued?

ONCY scores higher with a 3.4/10 quality rating vs OKYO's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing OKYO Pharma Limited (OKYO) and Oncolytics Biotech Inc. (ONCY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OKYO currently trades at $1.71 with a QOC of 1.7/10, while ONCY trades at $0.94 with a QOC of 3.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).